AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The PREDICT Registry:

Recruitingn/aAges 30 Years - 85 YearsFemalePreludeDx
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion criteria 1. Patient must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable). 2. Patient must have the DCISionRT test ordered during routine patient care. 3. Patient must be eligible for or have recently completed breast conserving surgery. 4. Patient must be eligible to receive radiation and/or systemic treatment. 5. Patient must be 30 to 85 years old. 6. Patient must have tumor size of less than 6 cm. 7. Patient must have been diagnosed with DCIS within 120 days of consent. Exclusion criteria 1. Patient tissue is insufficient to generate DCISionRT test results or required DCISionRT inputs (age, tumor size, margin status, palpability) are missing. 2. Patient has evidence of invasive breast cancer, including microinvasion, lymph node involvement, or Paget's disease of the nipple or suspicious mammogram findings in the lymph nodes or contralateral breast. 3. Patient has been surgically treated with an ipsilateral mastectomy for primary DCIS. 4. Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer. 5. Patient has a prior history of in-field radiation in the ipsilateral breast. 6. Patient has had prior systemic endocrine or chemotherapy prior to testing. 7. Patient is pregnant.
๐Ÿ’Š

What it tests

  • Treatment recommendation surveys
  • 7-gene biosignature
๐Ÿ“

Where

30 sites
Arizona Center for Cancer Care
Scottsdale, United States
University of California San Diego
La Jolla, United States
Sutter Health
San Mateo, United States
University of Colorado Anschutz Medical Campus
Aurora, United States
Baptist MD Anderson Cancer Center
Jacksonville, United States
BayCare Health System
Tampa, United States
University of South Florida
Tampa, United States
Emory University Winship Cancer Institute
Atlanta, United States

โ€ฆand 22 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy